Retinoids in biological control and cancer

Journal of Cellular Biochemistry

Volumn 102, Issue 4, 2007, Pages 886-898

  Fields, Anthonise Louis ^a   Soprano, Dianne Robert ^a   Soprano, Kenneth J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Differentiation; Growth arrest; Ovarian cancer; RAR RXR; Retinoic acid; Retinoids

Indexed keywords

RETINOID; RETINOL;

APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RETINOL DEFICIENCY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; HUMANS; NEOPLASMS; RETINOIDS; VITAMIN A; VITAMIN A DEFICIENCY;

EID: 35649008414     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21530     Document Type: Review

References (122)

1. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT Jr, LeRoith D, Fontana JA. 1992. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-bindingproteins (IGFBPs): IGFBP-2, -3, and-4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 131(4):1858-1866.
2. Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, Pelicci PG, Nervi C. 1997. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 90(3):1175-1185.
3. Blomhoff R, Blomhoff HK. 2006. Overview of retinoid metabolism and function. J Neurobiol 66(7):606-630.
4. Braud AC, Gonzague L, Bertucci F, Genre D, Camerlo J, Gravis G, Goncalves A, Moutardier V, Viret F, Maraninchi D, Viens P. 2002. Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: Clinical results of 2 phase II trials. Eur Cytokine Netw 13(1):115-120.
5. Chao WR, Hobbs PD, Jong L, Zhang XK, Zheng Y, Wu Q, Shroot B, Dawson MI. 1997. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH: OVCAR-3 ovarian cancer cell line in culture. Cancer Lett 115:1-7.
6. Chen JD, Evans RM. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377(6548):454-457.
7. Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT Jr, Fontana JA. 1994. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158(1):69-78.
8. Cohlan SQ. 1935. Excessive intakes of vitamin A as a cause of congenital anomalies in the rat. Science 117:535-536.
9. Costa A. 1993. Breast cancer chemoprevention. Eur J Cancer 29(4):589-592.
10. Costa A, De Palo G, Decensi A, Formelli F, Chiesa F, Nava M, Camerini T, Marubini E, Veronesi U. 1995. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann N Y Acad Sci 768:148-162.
11. De Luca LM. 1991. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 5:2924-2933.
12. De Palo G, Veronesi U, Marubini E, Camerini T, Chiesa F, Nava M, Formelli F, Del Vecchio M, Costa A, Boracchi P, et al. 1995. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. J Cell Biochem Suppl 22:11-17.
13. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV. 2007. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6(6):705-713.
14. del Rincon SV, Rousseau C, Samanta R, Miller WH Jr. 2003. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway. Oncogene 22(22):3353-3360.
15. del Rincon SV, Guo Q, Morelli C, Shiu HY, Surmacz E, Miller WH. 2004. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism. Oncogene 23(57):9269-9279.
16. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, Pfahl M. 1994. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372(6501):107-111.
17. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M, Qiu J. 1996. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271:22441-22446.
18. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. 1998. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci 95(18):10493-10498.
19. Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. 1983. Retinoic acid treatment of acute promyelocytic leukemia: In vitro and in vivo observations. Blood 62:1211-1217.
20. Fontana JA, Miksis G, Miranda DM, Durham JP. 1987. Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst 78(6):1107-1112.
21. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D. 1991. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 128(2):1115-1122.
22. Gibson SL, Ma Z, Shaw LM. 2007. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 6(6):631-637.
23. Giguere V, Ong ES, Segui P, Evans RM. 1987. Identification of a receptor for the morphogen retinoic acid. Nature 330:624-629.
24. Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, Elias PM, Lowe N, Nierenberg DW, Bayrd G, et al. 1990. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 323:789-795.
25. Hale F. 1937. Relation of maternal vitamin A deficiency to micropthalmia in pigs. Texas State J Med 33:228-232.
26. Hamada-Kanazawa M, Ishikawa K, Ogawa D, Kanai M, Kawai Y, Narahara M, Miyake M. 2004. Suppression of Sox6 in P19 cells leads to failure of neuronal differentiation by retinoic acid and induces retinoic acid-dependent apoptosis. FEBS Lett 577(1-2):60-66.
27. Han J, Jiao L, Lu Y, Sun Z, Gu QM, Scanlon KJ. 1990. Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 4:153-160.
28. Hansen K, Farkas T, Lukas J, Holm K, Ronnstrand L, Bartek J. 2001. Phosphorylation-dependent and -independent functions of p130 cooperate to evoke a sustained G1 block. EMBO J 20(3):422-432.
29. Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C, Grunt TW. 1993. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer 68:530-536.
30. Hislop TG, Band PR, Deschamps M, Ng V, Coldman AJ, Worth AJ, Labo T. 1990. Diet and histologic types of benign breast disease defined by subsequent risk of breast cancer. Am J Epidemiol 131(2):263-270.
31. Holmes WF, Dawson MI, Soprano RD, Soprano KJ. 2000. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J Cell Physiol 185(1):61-67.
32. Holmes WF, Soprano DR, Soprano KJ. 2002. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem 277(47):45408-45419.
33. Holmes WF, Soprano DR, Soprano KJ. 2003. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J Cell Biochem 89(2):262-278.
34. Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, Zhao L, Xie JX, Shen ZX, Wang ZY. 1987. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl) 100:949-953.
35. Huang ME, Ye YC, Chen SR, Chai J, Lu J, Zhoa L, Gu L, Wang Z. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-578.
36. Hultin TA, May CM, Moon RC. 1986. N-(4-hydroxyphenyl)-all-trans- retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos 14(6):714-717.
37. Jacobs S, Lie DC, DeCicco KL, Shi Y, DeLuca LM, Gage FH, Evans RM. 2006. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci USA 103(10):3902-3907.
38. James SY, Mackay AG, Colston KW. 1995. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14(3):391-394.
39. Jemal A, Ward E, Hao Y, Thun M. 2005. Trends in the leading causes of death in the United States, 1970-2002. JAMA 294(10):1255-1259.
40. Kark JD, Smith AH, Switzer BR, Hames CG. 1981. Serum vitamin A (retinol) and cancer incidence in Evans County, Georgia. J Natl Cancer Inst 66(1):7-16.
41. Kastner P, Mark M, Chambon P. 1995. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 83:859-869.
42. Kato S, Sasaki H, Suzawa M, Masushige S, Tora L, Chambon P, Gronemeyer H. 1995. Widely spaced, directly repeated PuGGTCA elements act as promiscuous enhancers for different classes of nuclear receptors. Mol Cell Biol 11:5858-5867.
43. Klaassen I, Braakhuis BJ. 2002. Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol 38(6):532-542.
44. Knoepfter PS, Kamps MP. 1997. The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - Evidence for selective targeting of E2a-Pbx1 to a subset of Pbx-recognition elements. Oncogene 14(21):2521-2531.
45. Koga M, Sutherland RL. 1991. Retinoic acid acts synergistically with 1, 25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 39(4A):455-460.
46. Langston AW, Gudas LJ. 1992. Identification of a retinoic acid responsive enhancer 3′ of the murine homeobox gene Hox-1.6. Mech Dev 38(3):217-227.
47. Langston AW, Thompson JR, Gudas LJ. 1997. Retinoic acid-responsive enhancers located 3′ of the Hox A and Hox B homeobox gene clusters. Functional analysis. J Biol Chem 272(4):2167-2175.
48. Lasnitzki I. 1976. Reversal of methylcholanthrene-induced changes in mouse prostates in vitro by retinoic acid and its analogues. Br J Cancer 34:239-248.
49. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW. 1998. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95(6):2920-2925.
50. Li R, Faria TN, Boehm M, Nabel EG, Gudas LJ. 2004. Retinoic acid causes cell growth arrest and an increase in p27 in F9 wild type but not in F9 retinoic acid receptor beta2 knockout cells. Exp Cell Res 294(1):290-300.
51. Lin RJ, Evans RM. Mol Cell. 2000. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5(5):821-830.
52. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. 1993. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20.
53. Litovchick L, Chestukhin A, DeCaprio JA. 2004. Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence. Mol Cell Biol 24(20):8970-8980.
54. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X. 1996. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16(3):1138-1149.
55. Ludlow JW, Glendening CL, Livingston DM, DeCarprio JA. 1993. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 13(1):367-372.
56. Marth C, Daxenbichler G, Dapunt O. 1986. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 77(6):1197-1202.
57. Marth C, Zech J, Bock G, Mayer I, Daxenbichler G. 1987. Effects of retinoids and interferon-gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha. Int J Cancer 40(6):840-845.
58. Marth C, Widschwendter M, Daxenbichler G. 1993. Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer cells. J Steroid Biochem Mol Biol 47(1-6):123-126.
59. Martinez-Ceballos E, Chambon P, Gudas LJ. 2005. Differences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal. J Biol Chem 280(16):16484-16498.
60. Mason KE. 1935. Fetal death, prolonged gestation, and difficult parturition in the rat as a result of vitamin A deficiency. Am J Anat 57:303-349.
61. Mayol X, Grana X. 1997. pRB, p107 and p130 as transcriptional regulators: Role in cell growth and differentiation. Prog Cell Cycle Res 3:157-169.
62. Mayol X, Grana X. 1998. The p130 pocket protein: Keeping order at cell cycle exit/re-entrance transitions. Front Biosci 3:d11-d24.
63. McGuire V, Herrinton L, Whittemore AS. 2002a. Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology 13(2):231-234.
64. McGuire V, Jesser CA, Whittemore AS. 2002b. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84(3):399-403.
65. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS. 1994. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-transretinoic acid: A randomized trial. J Natl Cancer Inst 86:539-543.
66. Miller WH Jr, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A III, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E. 2000. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 11(11):1387-1389.
67. Misset JL, Mathe G, Santelli G, Gouveia J, Homasson JP, Sudre MC, Gaget H. 1986. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev 9:167-170.
68. Moberg K, Starz MA, Lees JA. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16(4):1436-1449.
69. Moon RC. 1994. Vitamin A, retinoids and breast cancer. Adv Exp Med Biol 364:101-107.
70. Moon RC, Mehta RG. 1990. Chemoprevention of mammary cancer by retinoids. Basic Life Sci 52:213-224.
71. Moon RC, Grubbs CJ, Sporn MB. 1976. Inhibition of 7, 12-dimethylbenz(a) anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res 36(7 PT 2):2626-2630.
72. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB. 1979. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39(4):1339-1346.
73. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. 1992. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12(4):1147-1153.
74. Moon TE, Levine N, Cartmel B, Bangert JL. 1997. Retinoids in prevention of skin cancer. Cancer Lett 114:203-205.
75. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH. 1994. Retinoic acid and interferon in human cancer: Mechanistic and clinical studies. Semin Hematol 31 (4 Suppl 5):31-37.
76. Paggi MG, Baldi A, Bonetto F, Giordano A. 1996. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62(3):418-430.
77. Park JP, Fairweather RB. 1996. Complex t(1;15;17) in acute promyelocytic leukemia with duplication of RAR alpha and PML sequences. Cancer Genet Cytogenet 89(1):52-56.
78. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108.
79. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, Clerici M, Soresi E, Valente M, et al. 1993. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222.
80. Pozzi S, Rossetti S, Bistulfi G, Sacchi N. 2006. RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells. Oncogene 25(9):1400-1407.
81. Predki PF, Zambie D, Sarkar B, Giguère V. 1994. Ordered binding of retinoic acid and retinoid-X receptors to asymmetric response elements involves determinants adjacent to the DNA-binding domain. Mol Endocrinol 8(1):31-49.
82. Purev E, Giordano A, Soprano DR, Soprano KJ. 2006. Interaction of PP2A catalytic subunit with Rb2/p130 is required for all-trans retinoic acid suppression of ovarian carcinoma cell growth. J Cell Physiol 206(2):495-502.
83. Qin P, Haberbusch JM, Soprano KJ, Soprano DR. 2004. Retinoic acid regulates the expression of PBX1, PBX2, and PBX3 in P19 cells both transcriptionally and post-translationally. J Cell Biochem 92(1):147-163.
84. Rohan TE, Hartwick W, Miller AB, Kandel RA. 1998. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 90(17)1262-1269.
85. Roman SD, Clarke CL, Hall RE, Alexander IE, Sutherland RL. 1992. Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52(8):2236-2242.
86. Rowley JD, Golomb HM, Dougherty C. 1977. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1(8010):549-550.
87. Sanz MA. 2006. Treatment of acute promyelocytic leukemia. Hematol Am Soc Hematol Educ Program 147-155.
88. Saunders DE, Christensen C, Williams JR, Wappler NL, Lawrence WD, Malone JM, Malviya VK, Deppe G. 1995. Inhibition of breast and ovarian carcinoma cell growth by 1, 25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drug 6(4):562-569.
89. Schrader M, Wyss A, Sturzenbecker LJ, Grippo JF, LeMotte P, Carlberg C. 1993. RXR-dependent and RXR-independent transactivation by retinoic acid receptors. Nucleic Acids Res 21(5):1231-1237.
90. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. 1995. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ 6(9):1077-1088.
91. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA. 1995. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11(3):493-504.
92. Sheikh MS, Shao ZM, Hussain A, Chen JC, Roberts CT Jr, LeRoith D, Fontana JA. 1993a. Retinoic acid and estrogen modulation of insulin-like growth factor binding protein-4 gene expression and the estrogen receptor status of human breast carcinoma cells. Biochem Biophys Res Commun 193(3):1232-1238.
93. Sheikh MS, Shao ZM, Chen JC, Hussain A, Jetten AM, Fontana JA. 1993b. Estrogen receptor-negative breast cancer cells transfected with the estrogen receptor exhibit increased RAR alpha gene expression and sensitivity to growth inhibition by retinoic acid. J Cell Biochem 53(4):394-404.
94. Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M, Rochefort H, Fontana JA. 1994. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem 269(34):21440-21447.
95. Sheikh MS, Shao ZM, Li XS, Ordonez JV, Conley BA, Wu S, Dawson MI, Han QX, Chao WR, Quick T, et al. 1995. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16:2477-2486.
96. Shen S, Kruyt FA, den Hertog J, van der Saag PT, Kruijer W. 1991. Mouse and human retinoic acid receptor beta 2 promoters: Sequence comparison and localization of retinoic acid responsiveness. DNA Seq 2(2):111-119.
97. Shils ME, senior editor. 2006. Modern nutrition in health and disease 10th edition. Philadelphia: Lippincott Williams & Wilkins.
98. Smith EJ, Leone G, Nevins JR. 1998. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ 9(4):297-303.
99. Soprano DR, Soprano KJ. 2003. Pharmacological doses of some synthetic retinoids can modulate both the aryl hydrocarbon receptor and retinoid receptor pathways. J Nutr 133(1):277S-281S.
100. Soprano DR, Qin P, Soprano KJ. 2004. Retinoic acid receptors and cancers. Annu Rev Nutr 24:201-221.
101. Soprano KJ, Purev E, Vuocolo S, Soprano DR. 2006. Rb2/pl30 and protein phosphatase 2A: Key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene 25(38):5315-5325.
102. Tairis N, Gabriel JL, Soprano KJ, Soprano DR. 1995. Alteration in the retinoid specificity of retinoic acid receptor-beta by site-directed mutagenesis of Arg269 and Lys220. J Biol Chem 270(31):18380-18387.
103. Takase S, Ong DE, Chytil F. 1986. Transfer of retinoic acid from its complex with cellular retinoic acid-binding protein to the nucleus. Arch Biochem Biophys 247(2):328-334.
104. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, Menon PA, Benson PM, Mellette JR, Guill MA, et al. 1992. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: A multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 84(5):328-332.
105. Tedesco D, Lukas J, Reed SI. 2002. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 16(22):2946-2957.
106. Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A. 1993. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53(20):4769-4771.
107. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. 1998. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 2:293-304.
108. van der Burg B, van der Leede BM, Kwakkenbos-Isbrucker L, Salverda S, de Laat SW, van der Saag PT. 1993. Retinoic acid resistance of estradiol- independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol 91(1-2):149-157.
109. van der Leede BJ, Folkers GE, van den Brink CE, van der Saag PT, van der Burg B. 1995. Retinoic acid receptor alpha 1 isoform is induced by estradiol and confers retinoic acid sensitivity in human breast cancer cells. Mol Cell Endocrinol 109(1):77-86.
110. Veronesi U, Costa A. 1992. Breast cancer chemoprevention. Cancer Treat Res 60:357-367.
111. Veronesi U, Decensi A. 2001. Retinoids for ovarian cancer prevention: Laboratory data set the stage for thoughtful clinical trials. J Natl Cancer Inst 93(7):486-488.
112. Vuocolo S, Purev E, Zhang D, Bartek J, Hansen K, Soprano DR, Soprano KJ. 2003. Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced suppression of ovarian carcinoma cell growth. J Biol Chem 278:41881-41889.
113. Vuocolo S, Purev E, Zhang D, Bartek J, Hansen K, Soprano DR, Soprano KJ. 2004. p27/Kip1 mediates retinoic acid-induced suppression of ovarian carcinoma cell growth. J Cell Physiol 199(2):237-243.
114. Willhite CC, Dawson MI. 1990. Structure-activity relationships of retinoids in developmental toxicology. TV. Planar Cisoid conformational restriction. Toxicol Appl Pharmacol 103(2):324-344.
115. Wolbach SB, Howe PR. 1925. Tissue changes following deprivation of fat-soluble A vitamin. Nutr Rev 36:16-19.
116. Wu S, Donigan A, Platsoucas CD, Jung W, Soprano DR, Soprano KJ. 1997. All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. Exp Cell Res 232(2):277-286.
117. Wu S, Zhang D, Donigan A, Dawson MI, Soprano DR, Soprano KJ. 1998a. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J Cell Biochem 68:378-388.
118. Wu S, Zhang D, Zhang ZP, Soprano DR, Soprano KJ. 1998b. Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid. Oncogene 17:2839-2849.
119. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. 2000. Retinoids and ovarian cancer. J Cell Physiol 185(1):1-20.
120. Zhang D, Vuocolo S, Masciullo V, Sava T, Giordano A, Soprano DR, Soprano KJ. 2001. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 20(55):7935-7944.
121. Zhao Z, Zhang ZP, Soprano DR, Soprano KJ. 1995. Effect of 9-cis-retinoic acid on growth and RXR expression in human breast cancer cells. Exp Cell Res 219(2):555-561.
122. Zhuang Y, Faria TN, Chambon P, Gudas LJ. 2003. Identification and characterization of retinoic acid receptors beta2 target genes in F9 teratocarcinoma cells. Mol Cancer Res 1:619-630.